Rituximab treatment in rheumatoid arthritis: how does it work? |
| |
Authors: | Maria JH Boumans Paul P Tak |
| |
Affiliation: | 1. Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, 1100, Amsterdam, DE, the Netherlands
|
| |
Abstract: | Treatment with the chimerical monoclonal antibody rituximab results in CD20-directed B cell depletion. Although this depletion is almost complete in the peripheral blood of nearly all patients with rheumatoid arthritis, a proportion of patients does not exhibit a clinical response. The paper by Nakou and colleagues suggests that a decrease in CD19+CD27+ memory B cells in both peripheral blood and bone marrow precedes the clinical response to rituximab. This finding adds to the emerging evidence that lack of response to rituximab is associated with persistence of B lineage cells in specific body compartments. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|